Medtronic plc (MDT) Executive Summary Medtronic plc is a global medical‑technology company that designs and sells a wide range of devices and therapies, pairing durable operating profitability with strong cash generation and a conservative balance sheet. Financial Strengths The company’s financial strengths include sustained operating efficiency and cash conversion: operating margin is 22.2% and a
Medtronic plc is a global medical‑technology company that designs and sells a wide range of devices and therapies, pairing durable operating profitability with strong cash generation and a conservative balance sheet.
The company’s financial strengths include sustained operating efficiency and cash conversion: operating margin is 22.2% and average net margin is about 10.36%, while operating cash flow has consistently exceeded reported net income (operating cash flow / net income ≈ 1.5131) and the most recent TTM operating cash flow is $7.35B, supporting both reinvestment and shareholder payouts (Profit Margin Trends, Earnings Quality Analysis, Revenue & Net Income).
Notable areas of concern include margin and revenue per‑share dynamics: reported gross margin in the most recent annual period was -0.3% while net margin has slipped to roughly 10.4% from prior peaks (13.6%), and return on equity is modest at 9.2%—below typical 15% high‑ROE benchmarks (Profit Margin Trends, Return on Equity (ROE)).
Key fundamentals to watch going forward are operating cash flow (staying near or above the current $7.3B TTM level), trends in gross and net margins relative to the recent 10.4% net margin and -0.3% gross margin readings, ROE versus the 9.2% current level, three‑year EPS CAGR (~5.08%), and capital allocation flows (TTM investing -$3.49B and financing -$4.96B) alongside the evolving P/E multiple (most recent P/E ~26.2x).
The foundation of business quality and long-term value creation
Medtronic plc's revenue remained in a relatively narrow band around $7.3B–$7.8B for multiple quarters across 2016–2023, then rose to $9.02B in the most recent quarter (period ending 2026-01-23). Historical entries include several much larger quarters (e.g., $20.26B on 2015-04-24 and $15.51B on 2018-04-27), which stand out relative to the multi-year run of ~$7–8B quarterly receipts prior to the latest $9.02B print.
Net income for Medtronic plc has been more variable. After a low of $427.0M in the quarter ended 2022-10-28, net income rebounded to $1.22B in the quarter ended 2023-01-27, dipped to $791.0M and $909.0M in mid-to-late 2023, and then rose above $1.2B in 2024 and 2025 (peaking at $1.32B on 2024-01-26 and $1.29B on 2025-01-24). The most recent revenue was $9.02B and the most recent net income was $1.29B.
Why Growth Matters
Consistent revenue and earnings growth are the lifeblood of successful long-term investments. Companies that can grow their top line (revenue) and bottom line (net income) over many years demonstrate they have products or services customers value and are willing to pay for repeatedly.
Revenue Growth shows whether the company is expanding its market reach, gaining market share, or successfully launching new products.Net Income Growth demonstrates the company can convert that revenue into actual profits while managing costs effectively.
Look for steady, sustainable growth rather than erratic spikes. The best businesses compound earnings year after year, creating tremendous value for shareholders over time. Companies that can grow earnings faster than revenue are improving their profitability—a sign of operational excellence and competitive strength.
Year-over-year growth rates for revenue and earnings per share
Reading the Growth Rate Chart
This chart converts the absolute per-share figures into year-over-year percentage changes, making it easy to see whether growth is accelerating, decelerating, or reverting to trend — regardless of the company's absolute size.
Revenue per Share Growth (1-year, split-adjusted) measures how quickly the top line is expanding on a per-share basis. Sustained positive growth signals that the company continues to win customers and grow its addressable market.EPS Diluted Growth (1-year, split-adjusted) measures how quickly earnings are compounding for each shareholder. When EPS growth consistently outpaces revenue growth, operating leverage and margin expansion are at work.
Look for consistency, not just magnitude. A company that reliably grows EPS 10–15% per year is far more valuable than one that alternates between 50% spikes and deep contractions. Negative EPS growth during a period of positive revenue growth is a red flag — costs are rising faster than sales. Quarters where both lines converge near zero or go negative deserve close scrutiny.
How revenue converts to net income for the most recent annual period
Period Information
Report Type: Annual (10-K)
Period: Apr 2017 to Apr 2018
Analyzing long-term margin stability and competitive positioning
Medtronic plc’s net profit margin has moved lower in the most recent annual period. Trailing net margins were 13.2% (2015), 13.6% (2017) and declined to 10.4% in the period ending 2018-04-27, showing a year-over-year decrease from 13.6% to 10.4% between 2017 and 2018.
The most recent gross margin was -0.3%, the most recent operating margin was 22.2%, and the most recent net profit margin was 10.4%, indicating operating profitability substantially higher than the net outcome.
Understanding Profit Margins
Between Apr 2017 and Apr 2018, Medtronic Plc converts every dollar of revenue through the following stages:
Sustainable competitive advantages reveal themselves through consistently superior profit margins over extended periods. Companies with durable economic moats maintain pricing power and operational efficiency that competitors struggle to match.
A sign of durable competitive advantage is earning sustained higher margins than competitors.Look for margins that remain stable or improve over time, especially during economic downturns. Declining margins may signal increasing competition, pricing pressure, or deteriorating business fundamentals.
Comparing reported earnings to actual cash generation
Medtronic plc's operating cash flow (TTM) shows a multi-year upward trend, rising from $4.90B in 2015 to roughly $7.35B in the most recent 2022 period. The series steps up through intermediate observations of about $7.01B in 2019 and $7.23B in 2020, with the latest reported level holding near $7.35B in April 2022.
Trailing twelve‑month net income is more volatile over the same span: it increased from $2.67B in 2015 to $4.03B in 2017, dipped to $3.10B in 2018, and recovered to $4.63B in 2019. In the years where both metrics are reported, operating cash flow has exceeded net income (for example, 2019: $7.01B operating CF vs. $4.63B net income). The most recent Operating Cash Flow (TTM) observed was $7.35B (period ending 2022-04-29) and the most recent Net Income (TTM) observed was $4.63B (period ending 2019-04-26).
The Earnings vs. Cash Flow Gap
Reported earnings (Net Income) doesn't always reflect actual cash generation. Companies use accrual accounting, which recognizes revenue when earned and expenses when incurred—not when cash actually changes hands. This creates timing differences and opportunities for accounting discretion that can mask underlying business health.
Net Income (the "earnings" number) can be influenced by non-cash items like depreciation, stock-based compensation, and changes in accounting estimates.Operating Cash Flow, however, shows the actual cash the business generates from its core operations—a harder number to manipulate.
What to Look For
Key Insight: Companies with durable competitive advantages typically show operating cash flow that meets or exceeds net income over time, demonstrating they convert accounting profits into actual cash that can be returned to shareholders or reinvested in the business.
Measuring management's efficiency at generating profits from shareholder capital
Medtronic plc's trailing twelve-month return on equity moved from 8.0% for the period ending 2017-04-28 down to 6.1% in the 2018 period, then rebounded to 9.2% in the most recent 2019 period. The series shows a clear inflection between 2018 and 2019, when ROE rose by 3.1 percentage points after the prior-year decline of 1.9 percentage points.
The most recent ROE of 9.2% remains below the commonly cited 15% threshold for a "high" ROE. The most recent quarterly return on equity (ROE) was 9.2%.
The Gold Standard of Profitability
Return on Equity (ROE) is a powerful measure of how effectively a company's management is using the money shareholders have invested. Calculated by dividing Net Income by Shareholders' Equity, it reveals how much profit is generated for every dollar of equity capital.
A consistently high ROE (typically above 15-20%) is often the signature of a "quality" business with a durable competitive advantage. It indicates that the company can generate high returns on its own capital, which it can then reinvest at these high rates to compound value over time.
What to Look For:
How the company generates and deploys its cash
Medtronic plc's trailing twelve-month operating cash flow appears stable in the most recent data points, with the latest reported figure at $7.35B (period ending 2022-04-29). This represents a modest increase from earlier reported TTM operating cash flows of $7.01B (period ending 2019-04-26) and $7.23B (period ending 2020-04-24), indicating a relatively consistent operating cash generation across the available observations.
On the deployment side, investing cash flow has moved to larger net outflows in recent periods: the most recent investing cash flow TTM is -$3.49B (period ending 2023-04-28), compared with -$2.87B (period ending 2021-04-30) and -$1.97B (period ending 2019-07-26). Financing cash flow has also been a net outflow in the latest data, at -$4.96B (period ending 2023-04-28), which is smaller in magnitude than the larger financing outflow of -$11.95B reported for the period ending 2018-04-27.
The most recent operating cash flow (TTM) was $7.35B. The most recent investing cash flow (TTM) was -$3.49B. The most recent financing cash flow (TTM) was -$4.96B.
Understanding Company Strategy
Capital allocation refers to how management decides to spend and invest the company's cash. Analyzing the three primary categories of cash flow reveals a company's true operational strategy:
What to look for: Is the company bootstrapping (funding growth solely from operating cash)? Are they borrowing to fund aggressive expansion or dividends? Or are they capital raising by issuing new shares, potentially diluting your ownership? A healthy, mature company typically generates strong operating cash, moderately invests in growth, and returns the surplus to shareholders through financing activities.
Net assets attributable to each share — the accounting floor of intrinsic value
Why Book Value per Share Matters
Book value per share is the net worth of the company — total assets minus total liabilities — divided by shares outstanding (split-adjusted). It represents the theoretical liquidation value per share if every asset were sold and every liability repaid at balance-sheet carrying values. It is the accounting foundation upon which much of equity valuation is built.
A steadily rising book value per share is one of the most reliable signals of compounding wealth creation. It means the company is retaining earnings and building net worth faster than it is returning capital or eroding it. Warren Buffett famously tracked Berkshire Hathaway's book value per share for decades as his primary measure of intrinsic value growth.
Context is essential. Asset-heavy businesses (banks, manufacturers, utilities) should be judged by book value more directly than asset-light businesses (software, consumer brands), where intangible assets like intellectual property and customer loyalty may far exceed their balance-sheet carrying values. A company trading at a large premium to book value is not necessarily overvalued — it may simply possess competitive advantages that accounting rules do not capture. Conversely, a declining book value per share — especially over multiple years — is a serious warning sign of capital destruction.
How much of the company is financed by debt versus shareholders' equity
Reading the Debt-to-Equity Ratio
The debt-to-equity (D/E) ratio compares total financial debt to shareholders' equity. A ratio of 1.0 means the company has borrowed one dollar for every dollar of equity; a ratio of 2.0 means it has borrowed twice as much as it owns. Financial leverage amplifies both returns and risk: in good times, debt turbocharges equity returns; in bad times, it accelerates losses and can threaten solvency.
Trends matter more than a single number. A rising D/E ratio can mean the company is taking on debt to fund growth — potentially value-creating if returns exceed the cost of capital. But it can also mean equity is being eroded through losses or that the business is borrowing simply to sustain operations. A falling D/E ratio generally reflects strengthening financial health: earnings are being retained, debt maturities are being paid down, or both.
Industry norms vary enormously. Capital-intensive sectors (utilities, real estate, financials) routinely carry high D/E ratios that would be alarming in, say, a technology company. Always compare against sector peers. As a rough rule of thumb, a D/E above 2× in a cyclical business warrants careful scrutiny of interest coverage and refinancing risk.
Short-term liquidity — can the company cover its near-term obligations?
Liquidity: Can the Business Pay Its Bills?
The current ratio is calculated as current assets divided by current liabilities. A ratio of 1.5 means the company has $1.50 of short-term assets — cash, receivables, inventory — for every $1.00 of obligations due within the next twelve months. It is the most direct measure of near-term financial resilience: can the business meet its obligations without needing to raise new capital or sell long-term assets at a discount?
A ratio above 1.0 is generally healthy, meaning current assets exceed current liabilities. A ratio consistently above 2.0 may indicate the company is holding excess cash or inventory that could be deployed more productively. A ratio below 1.0 is a warning sign — the company is relying on future cash generation or external financing to cover its near-term obligations, which is manageable in normal conditions but dangerous during a downturn.
Trends and context matter.A declining current ratio isn't always alarming — highly efficient businesses (e.g., large retailers with reliable daily cash flows) often run leaner balance sheets intentionally. Conversely, a rapidly rising current ratio can signal slowing sales causing inventory to build, or customers taking longer to pay. Always compare the trend against industry peers and cross-reference with the cash flow statement to assess whether the business is genuinely liquid or just holding non-cash current assets.
How much the market is paying for each dollar of company earnings
Medtronic plc's trailing twelve-month Price-to-Earnings ratio varied across the reported periods. It was 40.4x in the 2015 period, declined to 28.7x in the 2017 period, climbed to 36.4x in 2018, and then fell to 26.2x in 2019. Notable inflection points are the drop from 40.4x to 28.7x (2015→2017), the rebound to 36.4x in 2018, and the subsequent decline to 26.2x in 2019.
Weighting the most recent observations, the P/E contracted from 36.4x in 2018 to 26.2x in 2019. The most recent Price-to-Earnings (P/E) ratio observed was 26.2x.
What Is the PE Ratio?
The Price-to-Earnings (PE) ratio is one of the most widely used valuation metrics in investing. It divides the current stock price by the company's earnings per share (EPS), revealing how much investors are willing to pay for each dollar of earnings. A high PE can signal that the market expects strong future growth, while a low PE may suggest undervaluation—or reflect genuine concerns about the company's prospects.
Context matters:PE ratios vary significantly across industries. High-growth technology companies routinely trade at PE ratios above 30x or 40x, while mature, low-growth sectors like utilities or financials often trade closer to 10–15x. Always compare a company's PE to its own history and its industry peers, not just an absolute number.
What to Look For:
Key Insight:The PE ratio is a snapshot of market sentiment and expectations. Tracking it over time alongside earnings trends reveals whether the market's valuation has expanded or contracted—and whether that change is justified by fundamentals.